Michelle Ols

Michelle Ols

Auto-generated profile, based on publicly available information

Michelle Ols

Obsidian Therapeutics, Cambridge, Massachusetts

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2018 in Science Signaling
Verified
Journal Article
Closed access
PDF file
KHKate L. Henry
Kate L. Henry
DKDebra Kellner
Debra Kellner
BBBekim Bajrami
Bekim Bajrami
JAJohn E. Anderson
John E. Anderson
MBMercedes Beyna
Mercedes Beyna
MOMichelle L. Ols
Michelle L. Ols
Members of the family of nuclear factor κB (NF-κB) transcription factors are critical for multiple cellular processes, including regulating innate and adaptive immune responses, cell proliferation, and cell survival. Canonical NF-κB complexes are retained in the cytoplasm by the inhibitory protein IκBα, whereas noncanonical NF-κB complexes are retained by p100. Although activation of canonical NF-κB signaling through the IκBα kinase complex is well studied, few regulators of the NF-κB–inducing kinase (NIK)–dependent processing of noncanonical p100 to p52 and the subsequent nuclear translocation of p52 have been identified. We discovered a role for cyclin-dependent kinase 12 (CDK12) in transcriptionally regulating the noncanonical NF-κB pathway. High-content phenotypic screening identified the compound 919278 as a specific inhibitor of the lymphotoxin β receptor (LTβR), and tumor necrosis factor (TNF) receptor superfamily member 12A (FN14)–dependent nuclear translocation of p52, but not of the TNF-α receptor–mediated nuclear translocation of p65. Chemoproteomics identified CDK12 as the target of 919278. CDK12 inhibition by 919278, the CDK inhibitor THZ1, or siRNA-mediated knockdown resulted in similar global transcriptional changes and prevented the LTβR- and FN14-dependent expression of MAP3K14 (which encodes NIK) as well as NIK accumulation by reducing phosphorylation of the carboxyl-terminal domain of RNA polymerase II. By coupling a phenotypic screen with chemoproteomics, we identified a pathway for the activation of the noncanonical NF-κB pathway that could serve as a therapeutic target in autoimmunity and cancer.

9 January 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
MIMara C. Inniss
Mara C. Inniss
SSSean G. Smith
Sean G. Smith
DLDan Jun Li
Dan Jun Li
BPBenjamin Primack
Benjamin Primack
DSDexue Sun
Dexue Sun
DSDhruv K. Sethi
Dhruv K. Sethi
Adoptive cell therapies (ACT) have shown reduced efficacy against solid tumor malignancies compared to hematologic malignancies, partly due to the immunosuppressive nature of the tumor microenvironment (TME). ACT efficacy may be enhanced with pleiotropic cytokines that remodel the TME; however, their expression needs to be tightly controlled to avoid systemic toxicities. Here we show T cells can be armored with membrane-bound cytokines with surface expression regulated using drug-responsive domains (DRDs) developed from the 260-amino acid protein human carbonic anhydrase 2 (CA2). The CA2-DRD can be stabilized in vitro and in vivo with the FDA-approved small-molecule CA2 inhibitor acetazolamide (ACZ). We develop conditional degrons using library-based screening of mutants and show characterization of one DRD using crystallography and molecular dynamics (MD) simulations. Using protein-engineering solutions to increase the valency of DRDs fused to the cargo we have developed “modulation hubs” and show tight regulation of membrane-bound cytokines IL2, IL12, IL15, IL21, IL23, and IFNα in genetically engineered T cells. Finally, CA2-DRD regulated IL12 mediates regulated efficacy in a solid tumor model. Regulation of pleotropic cytokines potentially paves the way to safely use these powerful cytokines in ACT for cancer treatment.

20 February 2026 in Cancer Immunology Research
Verified
Journal Article
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Autologous tumor-infiltrating lymphocyte (TIL) cell therapy is showing promising efficacy against immunologically “hot” tumors such as melanoma, cervical cancer, and renal cancer. However, generation of tumoricidal TILs from “cold” tumors with a low tumor mutational burden, such as many sarcoma types, poses a challenge due to limited infiltration of the tumor microenvironment (TME) with lymphocytes, low frequencies of tumor antigen–specific, high-affinity T cells, and incompletely understood mechanisms of immune-resistance prevailing in the TME. Here, we report the successful generation and expansion of TILs engineered with regulatable, membrane-bound IL15 (cytoTIL15 cells) from immune-excluded, paucicellular chondrosarcoma biopsies largely consisting of collagenous matrix and demonstrate that these cells have potent tumor-killing capacity in cell culture and in tumor spheroid models in the absence of exogenous IL2. Comprehensive spatial profiling of the TME revealed ubiquitous collagen and myeloid infiltration as major resistance mechanisms, whereas lymphocytic infiltration was largely restricted to peripheral regions of the tumors, a relevant consideration when sampling these tumors for TIL harvest. Moreover, we demonstrate that IL15 reduced the signaling threshold of T-cell receptors isolated from TIL clonotypes, increasing their infiltration and cytotoxicity in autologous 3D tumor models. These results suggest the possibility of developing an effective IL2-free TIL therapy for patients with immune-excluded tumors.

7 November 2022 in Journal for ImmunoTherapy of Cancer
Verified
Conference Paper
Open access
PDF file
RBRachel Burga
Rachel Burga
ZAZheng Ao
Zheng Ao
AAArman Aksoy
Arman Aksoy
SLScott Lajoie
Scott Lajoie
KPKyle Pedro
Kyle Pedro
MKMithun Khattar
Mithun Khattar
Background CytoTIL15® therapy is an IL2-independent, engineered TIL product which allows pharmacological control of membrane-bound IL15 (mbIL15). We have previously shown that cytoTIL15® TILs demonstrate enhanced persistence and anti-tumor efficacy in a human allogeneic melanoma PDX model. Here we use digital spatial profiling and single cell sequencing to characterize the RNA expression profile and phenotypic markers of tumor infiltrating immune cells as well as tumor cells in this model and compare the results to unengineered, IL2-dependent TIL. Methods cytoTIL15® therapy contains TILs engineered with mbIL15 under the control of a carbonic-anhydrase-2 drug responsive domain, regulated by the ligand acetazolamide (ACZ). cytoTIL15® cells were generated from human melanomas through a proprietary rapid expansion process. Expanded TILs were phenotyped and assayed for in vitro polyfunctionality, cytotoxicity, and frequency of tumor-associated antigen-specific TCR. In vivo phenotype and anti-tumor functionality was examined through adoptive transfer of TILs into NSG mice bearing subcutaneous, HLA-matched, patient-derived-xenograft (PDX) tumors expressing melanoma-associated antigen MART-1, in IACUC approved animal studies. Tumors, spleen, bone marrow, and blood were harvested 14-21 days following adoptive cell transfer and assessed by flow cytometry, GeoMx digital spatial profiling, and single cell sequencing for characterization of TIL and the tumor microenvironment (TME). Results cytoTIL15® cells demonstrated enrichment and reactivity for melanoma antigen-specific TCRs, while maintaining TCRβ diversity. Fifteen days post-ACT, tumors from animals treated with cytoTIL15® cells exhibited significantly (p=0.0175) higher frequency (3.4-fold) of TILs, in which MART-1 tetramer positive cells demonstrated increased T-cell factor 1 (TCF-1) and CD69 expression, and secreted significantly greater amounts of IFNγ and TNFα cytokines into the TME, compared to unengineered TILs with IL2. In addition, cytoTIL15® TILs had a distinct differential gene expression profile, demonstrating an increase in effector genes such as IL2RB, GZMB, GNLY and CCL5 and reduction in exhaustion-related genes such as EOMES. cytoTIL15® cells accumulating in the bone marrow exhibited a lower frequency of CD39+ terminally differentiated CD8+ T cells, while maintaining higher levels of memory phenotype makers. Conclusions In this allogeneic melanoma PDX model, cytoTIL15® cells showed a distinct profile of RNA expression and phenotypic markers, consistent with their increased persistence and anti-tumor efficacy. Interestingly, the subpopulation of cytoTIL15® cells reactive to tumor-associated antigen MART-1 displayed increased expression of TCF-1, which in melanoma patients has been associated with responses to immune checkpoint blockade, in addition to progression-free and overall survival. Ethics Approval All animal studies were IACUC approved.

2 June 2026
Verified
Other
Open access
PDF file
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Supplementary Table S1: IHC antibody clones and dilution factors

2 June 2026
Verified
Other
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Supplementary Table S2: Flow cytometry antibodies clones and dulution factors